Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD

Respiratory Medicine

Volumn 105, Issue 4, 2011, Pages 580-587

  Maltais, François ^a   Celli, Bartolome ^b   Casaburi, Richard ^c   Porszasz, Janos ^c   Jarreta, Diana ^d   Seoane, Beatriz ^d   Caracta, Cynthia ^e  

^a LAVAL UNIVERSITY   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d Almirall SA ^*  (Spain)

^e FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Aclidinium; Chronic obstructive pulmonary disease; Exercise endurance; Lung hyperinflation

Indexed keywords

ACLIDINIUM BROMIDE; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENDURANCE TRAINING; EXPIRATORY RESERVE VOLUME; FEMALE; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; LEG DISEASE; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOTAL LUNG CAPACITY; UNSPECIFIED SIDE EFFECT;

BRONCHODILATOR AGENTS; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TROPANES; VITAL CAPACITY;

EID: 79952279994     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.11.019     Document Type: Article

References (29)

1. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006;27(1):188-207. (Pubitemid 43092683)
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11): e442.
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-55. (Pubitemid 47403272)
4. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370(9589):765-73. (Pubitemid 47321908)
5. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006;119(10 Suppl. 1):21-31. (Pubitemid 44425292)
6. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171(5):446-52. (Pubitemid 40444244)
7. Foglio K, Carone M, Pagani M, Bianchi L, Jones PW, Ambrosino N. Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction. Respir Med 2000;94(3):256-63. (Pubitemid 30198076)
8. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171(6):591-7. (Pubitemid 40365414)
9. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160(2):542-9. (Pubitemid 29380670)
10. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163(6):1395-9. (Pubitemid 32506605)
11. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153(3):967-75. (Pubitemid 26081647)
12. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171(9):972-7. (Pubitemid 40616945)
13. Ambrosino N, Foglio K, Balzano G, Paggiaro PL, Lessi P, Kesten S. Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance. Int J Chron Obstruct Pulmon Dis 2008;3(4):771-80.
14. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997;112(2):336-40. (Pubitemid 27349421)
15. O'Donnell DE, Fluge T,Gerken F, Hamilton A,Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23(6):832-40. (Pubitemid 38807355)
16. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005;128(3):1168-78. (Pubitemid 41324392)
17. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19(2):217-24. (Pubitemid 34162820)
18. Gross NJ. Tiotropium bromide. Chest 2004;126(6):1946-53. (Pubitemid 39644003)
19. Jones PW, Agusti A, Chanez P, Magnussen H, Fabbri L, Maroni J, et al. A phase III study evaluating aclidinium bromide, a novel long-acting antimuscarinic, in patients with COPD: ACCLAIM/- COPD I [abstract]. Am J Respir Crit Care Med 2009;179:A6180.
20. Rennard S, Donohue J, Bateman E, Gross NJ, Garcia Gil E, Caracta C. Efficacy and safety of the novel, long-acting antimuscarinic, Aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [abstract]. Am J Respir Crit Care Med 2009;179:A6178.
21. Sentellas S, Ramos I, Alberti J, Salva M, Anton F, Miralpeix M, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010;39(5):283-90.
22. Jansat JM, Lamarca R, de Miquel G, Schrodter A, Miletzki B, Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 2009;49(10): 1239-46.
23. Jansat JM, Lamarca R, Garcia Gil E, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009;47(7):460-8.
24. Mahler DA, Tomlinson D, Olmstead EM, Tosteson AN, O'Connor GT. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995;151(1):61-5.
25. Casaburi R. Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions. COPD 2005;2(1):131-6. (Pubitemid 40776233)
26. Laviolette L, Bourbeau J, Bernard S, Lacasse Y, Pepin V, Breton MJ, et al. Assessing the impact of pulmonary rehabilitation on functional status in COPD. Thorax 2008;63(2): 115-21. (Pubitemid 351236472)
27. O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006;130(3):647-56. (Pubitemid 44423592)
28. Albuquerque AL, Nery LE, Villaca DS, Machado TY, Oliveira CC, Paes AT, et al. Inspiratory fraction and exercise impairment in COPD patients GOLD stages II-III. Eur Respir J 2006;28(5): 939-44. (Pubitemid 46331962)
29. Mahler DA, Witek Jr TJ. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005;2(1): 99-103. (Pubitemid 40776229)